These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8439632)

  • 1. Short report: a non-metronidazole triple therapy for eradication of Helicobacter pylori infection--tetracycline, amoxicillin, bismuth.
    Graham DY; Lew GM; Ramirez FC; Genta RM; Klein PD; Malaty HM
    Aliment Pharmacol Ther; 1993 Feb; 7(1):111-3. PubMed ID: 8439632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing the eradication of Helicobacter pylori with triple therapy.
    Graham DY; Lew GM; Malaty HM; Evans DG; Evans DJ; Klein PD; Alpert LC; Genta RM
    Gastroenterology; 1992 Feb; 102(2):493-6. PubMed ID: 1732120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial.
    Laine L; Hunt R; El-Zimaity H; Nguyen B; Osato M; Spénard J
    Am J Gastroenterol; 2003 Mar; 98(3):562-7. PubMed ID: 12650788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study.
    Graham DY; Lew GM; Klein PD; Evans DG; Evans DJ; Saeed ZA; Malaty HM
    Ann Intern Med; 1992 May; 116(9):705-8. PubMed ID: 1558340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN; Hahm JS; Kim HJ
    Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection.
    al-Assi MT; Ramirez FC; Lew GM; Genta RM; Graham DY
    Am J Gastroenterol; 1994 Aug; 89(8):1203-5. PubMed ID: 8053435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
    Laine L; Estrada R; Trujillo M; Emami S
    Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized, controlled study of efficacy and side effects.
    Thijs JC; van Zwet AA; Moolenaar W; Wolfhagen MJ; ten Bokkel Huinink J
    Am J Gastroenterol; 1996 Jan; 91(1):93-7. PubMed ID: 8561152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
    Salmanroghani H; Mirvakili M; Baghbanian M; Salmanroghani R; Sanati G; Yazdian P
    PLoS One; 2018; 13(6):e0197096. PubMed ID: 29889843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Helicobacter pylori and gastric or duodenal ulcer.
    Prescrire Int; 2016 Jan; 25(167):18-23. PubMed ID: 26942258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
    Kahramanoğlu Aksoy E; Pirinçci Sapmaz F; Göktaş Z; Uzman M; Nazlıgül Y
    Med Princ Pract; 2017; 26(6):523-529. PubMed ID: 29131124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori.
    Kadayifci A; Uygun A; Polat Z; Kantarcioğlu M; Kılcıler G; Başer O; Ozcan A; Emer O
    Turk J Gastroenterol; 2012 Feb; 23(1):8-13. PubMed ID: 22505373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease.
    Graham DY; Hepps KS; Ramirez FC; Lew GM; Saeed ZA
    Scand J Gastroenterol; 1993 Nov; 28(11):939-42. PubMed ID: 8284627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness of triple therapy to eradicate H. pylori in patients after failed therapy with omeprazole/amoxicillin].
    Zala G; Schwery S; Giezendanner S; Flury R; Wüst J; Meyenberger C; Wirth HP
    Schweiz Med Wochenschr; 1996 Feb; 126(5):153-8. PubMed ID: 8685685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey.
    Gungor G; Baglıcakoglu M; Kayacetin E; Biyik M; Ucar R; Goktepe H; Ataseven H; Demir A
    Digestion; 2015; 92(2):55-9. PubMed ID: 26183105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
    Kung NN; Sung JJ; Yuen NW; Ng PW; Wong KC; Chung EC; Lim BH; Choi CH; Li TH; Ma HC; Kwok SP
    Am J Gastroenterol; 1997 Mar; 92(3):438-41. PubMed ID: 9068464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of intragastric acidity on Helicobacter pylori eradication with bismuth-metronidazole-amoxicillin.
    Chang CS; Yang CY; Wong FN; Chen GH; Lien HC; Yeh HZ; Poon SK
    Hepatogastroenterology; 1999; 46(28):2713-7. PubMed ID: 10522070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study.
    Labenz J; Stolte M; Peitz U; Tillenburg B; Köhl H; Becker T; Börsch G
    Z Gastroenterol; 1995 Oct; 33(10):590-3. PubMed ID: 7502551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.